Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer ...Middle East

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the...

Hence then, the article about akeso receives fifth breakthrough therapy designation from nmpa for ivonescimab in first line treatment of advanced biliary tract cancer was published today ( Friday 06/02/2026 - 05:38 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer )

Also on site :

• Blackpink’s Jisoo to Receive Madame Figaro Rising Star Award at Canneseries
• Walmart's 'Beautiful' Midcentury Modern TV Stand 'Looks More Expensive Than It Is,' and It's Now Only $62
• Family sues ChatGPT-maker OpenAI over school shooting in Canada